Induction of activating transcription factor 1 by nickel and its role as a negative regulator of thrombospondin I gene expression

Cancer Research

Volumn 57, Issue 22, 1997, Pages 5060-5066

  Salnikow, Konstantin ^a   Wang, Sheng ^a,b   Costa, Max ^a  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^b Columbia University Medical School ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NICKEL; THROMBOSPONDIN; TRANSCRIPTION FACTOR;

ANIMAL CELL; ARTICLE; CELL ADHESION; CELL GROWTH; CELL MOTILITY; CELL STRAIN 3T3; CONTROLLED STUDY; EXTRACELLULAR MATRIX; GENE EXPRESSION; MALIGNANT TRANSFORMATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SOLID TUMOR;

3T3 CELLS; ACTIVATING TRANSCRIPTION FACTOR 1; ANIMALS; BINDING SITES; CELLS, CULTURED; DNA-BINDING PROTEINS; GENE EXPRESSION; GENES, REPORTER; GENETIC VECTORS; METHYLATION; MICE; NICKEL; POLYMERASE CHAIN REACTION; PROMOTER REGIONS (GENETICS); THROMBOSPONDIN 1; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC; TRANSFECTION;

EID: 0030690087     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Frazier, W. A. Thrombospondin: a modular adhesive glycoprotein of platelets and nucleated cells. J. Cell Biol., 105: 625-632, 1987.
2. Mosher, D. F. Physiology of thrombospondin. Annu. Rev. Med., 41: 85-97, 1990.
3. Varani, J., Nickoloff, B. J., Riser, B. L., Mitra, R. S., O'Rourke, K., and Dixit, V. M. Thrombospondin-induced adhesion of human keratinocytes. J. Clin. Invest., 81: 1537-1544, 1988.
4. Taraboletti, G., Roberts, D. D., and Liotta, L. A. Thrombospondin-induced tumor cell migration: haptotaxis and chemotaxis are mediated by different molecular domains. J. Cell Biol., 105: 2409-2415, 1987.
5. Iruela-Arispe, M. L., Liska, D. J., Sage, E. H., and Bornstein, P. Differential expression of thrombospondin I, 2, and 3 during murine development. Dev. Dyn., 197: 40-56, 1993.
6. O'Shea, K. S., Liu, L-H. J., Kinnunen, L. H., and Dixit, V. M. The role of the extracellular matrix protein thrombospondin in the early development of the mouse embryo. J. Cell Biol., 111: 2713-2723, 1990.
7. Reed, M. J., Puolakkainen, P., Lane, T. F., Dickerson, D., Borastein, P., and Sage, E. H. Different expression of SPARC and thrombospondin I in wound repair: immunolocalization and in situ hybridization. J. Histochem. Cytochem., 41: 1467-1477, 1993.
8. McGregor, B., Colon, S., Mutin, M., Chignier, E., Xech, P., and McGregor, J. Thrombospondin in human glomerulopathies: a marker of inflammation and early fibrosis. Am. J. Pathol., 144: 1281-1287, 1994.
9. DiPietro, L. A., Nebgen, D. R., and Polverini, P. J. Downregulation of endothelial cell thrombospondin I enhances in vitro angiogenesis. J Vasc. Res., 31: 178-185, 1994.
10. Rastinejad, F., Polverini, P. J., and Bouck, N. P. Regulation of the activity of a new inhibitor of angiogenesis by a cancer suppressor gene. Cell, 56: 345-355, 1989.
11. Sheibani, N., and Frazier, W. A. Thrombospondin I expression in transformed endothelial cells restores a normal phenotype and suppresses their tumorigenesis. Proc. Natl. Acad. Sci. USA, 92: 6788-6792, 1995.
12. Tolsma, S. S., Volpert, O. V., Good, D. J., Frazier, W. A., Polverini, P. J., and Bouck, N. Peptides derived from two separate domains of the matrix protein thrombospondin-I have anti-angiogenic activity. J. Cell Biol., 122: 497-511, 1993.
13. Weinstat-Saslow, D. L., Zabrenetzky, V. S., VanHoutte, K., Frazier, W. A., Roberts, D. D., and Steeg, P. S. Transfection of thrombospondin I complementary DNA into a human breast carcinoma cell line reduces primary tumor growth, metastatic potential, and angiogenesis. Cancer Res., 54: 6504-6511, 1994.
14. Yabkowitz, R., Mansfield, P. J., Dixit, V. M., and Suchard, S. J. Motility of human carcinoma cells in response to thrombospondin: relationship to metastatic potential and thrombospondin structural domains. Cancer Res., 53: 378-387, 1993.
15. Mettouchi, A., Cabon, F., Montreau, N., Vernier, P., Mercier, G., Blangy, D., Tricoire, H., Vigier, P., and Binetruy, B. SPARC and thrombospondin genes are repressed by the c-jun oncogene in rat embryo fibroblasts. EMBO J., 13: 5668-5678, 1994.
16. Salnikow, K., Cosentino, S., Klein, C., and Costa, M. Loss of thrombospondin transcriptional activity in nickel-transformed cells. Mol. Cell. Biol., 14: 851-858, 1994.
17. Slack, J. L., and Bornstein, P. Transformation by v-src causes transient induction followed by repression of mouse thrombospondin-1. Cell Growth Differ., 5: 1373-1380, 1994.
18. Hogg, P. J. Thrombospondin I as an enzyme inhibitor. Thromb. Haemostasis, 72: 787-792, 1994.
19. Bornstein, P., Devarayalu, S., Li, P., Disteche, C. M., and Framson, P. A second thrombospondin gene in the mouse is similar in organization to thrombospondin I but does not respond to serum. Proc. Natl. Acad. Sci. USA, 88: 8636-8640, 1991.
20. Majack, R. A., Mildbrandt, J., and Dixit, V. M. Induction of thrombospondin messenger RNA levels occurs as an immediate primary response to platelet-derived growth factor. J. Biol. Chem., 262: 8821-8825, 1987.
21. Bornstein, P., Alfi, D., Devarayalu, S., Framson, P., and Li, P. Characterization of the mouse thrombospondin gene and evaluation of the role of the first intron in human gene expression. J. Biol. Chem., 265: 16691-16698, 1990.
22. Framson, P., and Bornstein, P. A serum responsive element and binding site for NF-Y mediate the serum response of the human thrombospondin I gene. J. Biol. Chem., 268: 4989-4996, 1993.
23. Good, D. J., Polverini, P. J., Rastinejad, F., Le Beau, M. M., Lemons, R. S., Frazier, W. A., and Bouck, N. P. A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc. Natl. Acad. Sci. USA, 87: 6624-6628, 1990.
24. Dameron, K. M., Volpert, O. V., Tainsky, M. A., and Bouck, N. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin I. Science (Washington DC), 265: 1582-1584, 1994.
25. Laherty, C. D., Gierman, T. M., and Dixit, V. M. Characterization of the promoter region of the human thrombospondin gene. J. Biol. Chem., 264: 11222-11227, 1989.
26. Lawler, J., Duquette, M., Ferro, P., Copeland, N. G., Gilbert, D. J., and Jenkins, N. A. Characterization of the murine thrombospondin gene. Genomics, 11: 587-600, 1991.
27. Shingu, T., and Bornstein, P. Overlapping Egr-1 and Sp1 sites function in the regulation of transcription of the mouse thrombospondin I gene. J. Biol. Chem., 269: 32551-32557, 1994.
28. Wang, X-W., Imbra, R. J., and Costa, M. Characterization of mouse cell lines resistant to nickel(II) ions. Cancer Res., 48: 6850-6854, 1988.
29. Imbra, R. J., Wang, X-W., and Costa, M. Mouse cells selected for nickel resistance exhibit a transformed phenotype. Proc. Am. Assoc. Cancer Res., 30: 733, 1989.
30. Deng, W. P., and Nickoloff, J. A. Site-directed mutagenesis of virtually any plasmid by eliminating a unique site. Anal. Biochem., 200: 81-88, 1992.
31. Dignam, J. D., Lebovitz, R. M., and Roeder, R. G. Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acids Res., 11: 1475-1489, 1983.
32. Combates, N. J., Rzepka, R. W., Chen, Y-N. P., and Cohen, D. NF-IL6, a member of the C/EBP family of transcription factors, binds and trans-activates the human MDR1 gene promoter. J. Biol. Chem., 269: 29715-29719, 1994.
33. Nakajima, T., Kinoshita, S., Sasagawa, T., Sasaki, K., Naruto, M., Kishimoto, T., and Akira, S. Phosphorylation at threonine-235 by a ras-dependent mitogen-activated protein kinase cascade is essential for transcription factor NF-IL6. Proc. Natl. Acad. Sci. USA, 90: 2207-2211, 1993.
34. Kim, S-J., Onwuta, U. S., Lee, Y. I., Li, R., Botchan, M. R., and Robbins, P. D. The retinoblastoma gene product regulates Sp1-mediated transcription. Mol. Cell. Biol., 12: 2455-2463, 1992.
35. Kim, S-J., Lee, H-D., Robbins, P. D., Busam, K., and Sporn, M. B. Regulation of transforming growth factor β 1 gene expression by the product of the retinoblastoma susceptibility gene. Proc. Natl. Acad. Sci. USA, 88: 3052-3056.
36. Ellis, M. J. C., Lindon, A. C., Flint, K. J., Jones, N. C., and Goodbourn, S. Activating transcription factor-1 is a specific antagonist of the cyclic adenosine 3′,5′-monophosphate (cAMP) response element-binding protein-1-mediated response to cAMP. Mol. Endocrinol., 9: 255-266, 1995.
37. Hai, T., Liu, F., Coukos, W. J., and Green, M. R. Transcription factor ATF cDNA clones: an extensive family of leucine zipper proteins able to selectively form DNA-binding heterodimers. Genes Dev., 3: 2083-2090, 1989.
38. Karpinski, B. A., Morle, G. D., Huggenvik, J., Uhler, M. D., and Leiden, J. M. Molecular cloning of human CREB-2: an ATF/CREB transcription factor that can negatively regulate transcription from the cAMP response element. Proc. Natl. Acad. Sci. USA, 89: 4820-4824, 1992.
39. Hurst, H. C., Totty, N. F., and Jones, N. C. Identification and functional characterization of the cellular activating transcription factor 43 (ATF-43) protein. Nucleic Acids Res., 19: 4601-4609, 1991.
40. Lee, Y-W., Klein, C. B., Kargacin, B., Salnikow, K., Kitahara, J., Dowjat, K., Zhitkovich, A., Christie, N. T., and Costa, M. Carcinogenic nickel silences gene expression by chromatin condensation and DNA methylation: a new model for epigenetic carcinogens. Mol. Cell. Biol., 15: 2547-2557, 1995.
41. Flessel, C. P. Metals as mutagens. In: G. N. Schrauzer (ed.), Inorganic and Nutritional Aspects of Cancer, pp. 117-128. New York: Plenum Press, 1978.
42. Fletcher, G. G., Rosetto, F. E., Turnbull, J. D., and Nieboer, E. Toxicity, uptake, and mutagenicity of particulate and soluble nickel compounds. Environ. Health Perspect., 102 (Suppl. 3): 69-79, 1994.
43. Kargacin, B., Klein, C. B., and Costa, M. Mutagenic responses of nickel oxides and nickel sulfides in Chinese hamster V79 cell lines at the xanthine-guanine phosphoribosyl transferase locus. Mutat. Res., 300: 63-72, 1993.
44. Morita, H., Umeda, M., and Ogawa, I. Mutagenicity of various chemicals including nickel and cobalt compounds in cultured mouse FM3A cells. Mutat. Res., 261: 131-137, 1991.
45. Trott, D. A., Cuthbert, A. P., Overell, R. W., Russo, I., and Newbold, N. F. Mechanisms involved in the immortalization of mammalian cells by ionizing radiation and chemical carcinogens. Carcinogenesis (Lond.), 16: 193-204, 1995.
46. Conway, K., and Costa, M. Nonrandom chromosomal alterations in nickel-transformed Chinese hamster embryo fibroblasts. Cancer Res., 49: 6032-6038, 1989.
47. Goetz, J., Chatton, B., Mattei, M-G., and Kedinger, C. Structure and expression of the ATFa gene. J. Biol. Chem., 271: 29589-29598, 1996.
48. Hsueh, Y-P., and Lai, M-Z. Overexpression of activation transcriptional factor 1 in lymphomas and in activated lymphocytes. J. Immunol., 154: 5675-5683, 1995.
49. Sakai, T., Ohtani, N., McGee, T. L., Robbins, P. D., and Dryja, T. P. Oncogenic germ-line mutations in SPI and ATF sites in the human retinoblastoma gene. Nature (Lond.), 353: 83-86, 1991.
50. Maechle, L., Metcalf, R. A., Ryberg, D., Bennett, W. P., Harris, C. C., and Haugen, A. Altered p53 gene structure and expression in human epithelial cells after exposure to nickel. Cancer Res., 52: 218-221, 1992.